Profiling imaging factors in prostate cancer treatment outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather data on the radiological and clinical progression of prostate cancer by utilizing multiparametric MRI (mpMRI) to identify imaging-based prognostic markers. Participants, men aged 18 and older with diagnosed or suspected prostate cancer, will allow researchers to access their medical history and imaging results for analysis. The goal is to enhance diagnosis and treatment decisions through the development of a decision-support system that incorporates imaging and clinical data.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:
* Patients with an increased risk for prostate cancer (strong family history and/or germline mutation in DNA repair genes), or with a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.
* Age greater than or equal to 18 years
* Ability of subject to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

-none

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Ismail B Turkbey, M.D. — National Cancer Institute (NCI)
• Study coordinator: Yolanda L McKinney, R.N.
• Email: ymckinney@mail.nih.gov
• Phone: (240) 760-6095

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using a new type of PET scanner for imaging prostate cancer and related conditions

  This study is testing a new type of PET scanner to see if it can better detect early signs of prostate cancer and related conditions in patients.

  Recruiting Jagiellonian University · Krakow · NCT06242119

• Investigating prostate medication effects on gut microbiota

  This study is testing how prostate medications affect the gut bacteria in men with prostate issues and whether those bacteria influence how well the medications work.

  Recruiting at 2 sites Phase 4 Turku University Hospital · Turku and 1 other locations · NCT06001619

• Comparing two versus five MRI-guided treatments for prostate cancer

  This study is testing if giving radiation treatment for prostate cancer in just two sessions instead of five can work just as well for men with localized prostate cancer.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT05600400

• Collecting blood samples from prostate cancer patients

  This study is collecting blood samples from men with prostate cancer to see if genetic differences affect how the disease progresses.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00923221

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.